All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The world is emerging from the COVID-19 pandemic, as both cases and deaths have remained consistently low in recent months, despite continuous mutation of the SARS-CoV-2 virus. Nevertheless, there is a shuffling of candidates in the arsenal as new variants bump once-effective therapies and the next generation of options enter the arena.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascendis, Biogen, Hexaell, Ideaya, Idorsia, Pfizer, Protalix, Redhill, Syndax.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anaptysbio, Altamira, Anavex, EIP, H. Lundbeck, Mirati, Ondine, Otsuka, Qilu, SK, Theratechnologies, Urogen, Vanda, Vaxxinity, Ventyx.
Investigators at the University of Bristol and Biognos AB have identified a structural feature that distinguished the deadly coronavirus strains from harmless, common cold-causing variants. The findings, which were published in the Nov. 23, 2022, issue of Science Advances, could form the basis of universal COVID antivirals, putting an end to the endless race to deal with new variants that has so far been a necessity.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aldeyra, Aurinia, Bluejay, Citius, Eli Lilly, Ferring, Innoviva, Nuvectis, Oncolytics, Opus Genetics, Orchard, Pyxis, Scynexis, Sparingvision.
The world is emerging from the COVID-19 pandemic, as both cases and deaths have remained consistently low in recent months, despite continuous mutation of the SARS-CoV-2 virus. Nevertheless, there is a shuffling of candidates in the arsenal as new variants bump once-effective therapies and the next generation of options enter the arena.
Quantbiores A/S has discovered peptides acting as spike glycoprotein (S) (SARS-CoV-2)/ACE2 interaction inhibitors reported to be useful for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19).
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aldeyra, Ascletis, Buchang, Capstone, Caribou, Genentech, Gilead, Kala, Novavax, Remd, Sofie.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Atea, Biovie, Hansa, Inversago, Mebias, Mirum, Netris, Tyra.
RSS
